CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 175 enrolled
Drug / intervention
Ramucirumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02443324
NCT02443324Phase 1Completed
CompareCT.gov

An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Eli Lilly and Company·interventional·Posted May 13, 2015·Updated Jul 31, 2024

In Brief

A Phase 1 clinical trial evaluating Ramucirumab and Pembrolizumab for Gastric Adenocarcinoma and 4 related conditions. Completed, enrolled 175 participants across 22 sites in 6 countries.

Detailed Summary

The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), transitional cell carcinoma of the urothelium, or biliary tract cancer (BTC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer
CountriesFrance, Germany, Japan, Spain, United Kingdom, United States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 13, 2015
Enrollment StartJul 29, 2015
Primary CompletionAug 31, 2018
Study CompletionApr 12, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.1 years ago

Interventions

Ramucirumabdrug

Administered IV

Pembrolizumabdrug

Administered IV